Medical Condition News

RSS

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Overweight infants may experience delayed motor skills

Those cute little rolls of fat some infants have may actually slow their ability to crawl and walk, according to a new study by the University of North Carolina at Chapel Hill.

31 Mar 2010

Study indicates estrogenic drug could help treat schizophrenia

An estrogenic drug that influences neurotransmitter and neuronal systems in the brain is showing promise as an effective therapy for women who suffer from schizophrenia.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Vision CRC scientists discover new technology to control myopia

Scientists from the Vision Cooperative Research Centre in Australia today announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners - the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

31 Mar 2010

Women, diabetics, dementia patients most likely to fall in 'doughnut hole'; Reform seeks to close coverage gap

Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

SpineAlign Medical announces VerteLift as new name for vertebral implant system

SpineAlign Medical Inc. announced today that it has chosen a new trademark name, VerteLift, for its vertebral implant system. Formerly called the SpineAlign System, the name reflects the advantages of the product that the Company will leverage going forward.

30 Mar 2010

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.

30 Mar 2010

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

By blocking the cellular signaling activity of a protein, a team of neuroscientists at Cold Spring Harbor Laboratory (CSHL) has prevented memory loss in fruit flies caused by brain plaques similar to those thought to cause Alzheimer's disease in humans. The study also resolves a long-standing controversy about the role of this protein, PI3 kinase, which was previously thought to have a protective function against the disease.

30 Mar 2010

Genetically manipulating rats to emulate Alzheimer's disease in humans

Prof. Claudio Cuello at McGill University and his collaborators have genetically manipulated rats that can emulate Alzheimer's disease in humans, enabling research that will include the development of new treatments. Alzheimer's is a devastating brain condition leading to a progressive decline of memory and other brain functions. Although research mice have been developed in the past, rats are more intelligent than other rodents and the behavior of these rats is rich and predictable, which means that for the first time researchers will be able to detect and study the evolution of learning and memory deficits.

30 Mar 2010

Campbell Soup honored for commitment to food allergy safety, awareness and education

Campbell Soup Company was recently honored by the Food Allergy and Anaphylaxis Network for its commitment to food allergy safety, awareness and education.

30 Mar 2010

Mood altering effects of Phenytoin

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties.

30 Mar 2010

Wellness Formulations introduces Dermal Renu Sunshield

Wellness Formulations, LLC, a leader in anti-glycation research and product development, has launched Dermal Renu® Sunshield daily wear SPF 15 sunscreen. This mineral based sunscreen provides broad-spectrum protection from sun damage caused by UVA/UVB rays, while fighting the signs of aging through a unique combination of anti-glycation agents, antioxidants, moisturizing elements, peptides, and botanical extracts.

30 Mar 2010

Cumberland Pharmaceuticals submits Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for the use of Acetadote® (acetylcysteine) Injection in patients with non-acetaminophen acute liver failure. Acetadote was launched by Cumberland in 2004 as the first U.S.-approved injectable drug to treat acetaminophen overdose.

30 Mar 2010

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

Preliminary research on cancer treatments using nanotechnology and laser therapy has led to a National Science Foundation (NSF) Faculty Early Career Development (CAREER) award for Marissa Nichole Rylander, Virginia Tech assistant professor jointly appointed in the Department of Mechanical Engineering and Virginia Tech - Wake Forest University School of Biomedical Engineering and Sciences (SBES).

30 Mar 2010

Medical Condition News

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Patients switching to Victoza experience further reductions in A1c and weight loss

Overweight infants may experience delayed motor skills

Study indicates estrogenic drug could help treat schizophrenia

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

Vision CRC scientists discover new technology to control myopia

Women, diabetics, dementia patients most likely to fall in 'doughnut hole'; Reform seeks to close coverage gap

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

SpineAlign Medical announces VerteLift as new name for vertebral implant system

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

Genetically manipulating rats to emulate Alzheimer's disease in humans

Campbell Soup honored for commitment to food allergy safety, awareness and education

Mood altering effects of Phenytoin

Wellness Formulations introduces Dermal Renu Sunshield

Cumberland Pharmaceuticals submits Acetadote sNDA for non-acetaminophen acute liver failure

Virginia Tech professor receives NSF CAREER award for research on cancer therapies using nanotechnology

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News